REFERENCES
- UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854–865.
- Holman RR, Paul SK, Bethel MA, Matthews DR, Neil AW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577–1589.
- The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Eng J Med 2008;358:2545–2559.
- The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560–2572.
- Duckworth W, Abraira C, Moritz T, Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129–139.
- Riddle MC, Ambrosius WT, Brillon DJ, Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care 2010;33:983–990.
- Iwamoto Y, Taniguchi T, Nonaka K, Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus. Endocr J 2010;57:383–394.
- Iwamoto Y, Tajima N, Kadowaki T, Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial. Diabetes Obes Metab 2010;12(7):613–622.
- Horiuchi H. Diet therapy for diabetes mellitus – Diet therapy and its present status. J Jpn Soc Food Nutr 1954;5:426–431. (in Japanese).
- The Committee of Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. J Jpn Diabetes Soc 2010;53(6):450–467.
- Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 1999;22(6):920–924.
- Ray KK, Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009;373:1765–1772.
- Norris SL, Lau J, Smith SJ, Schmid CH, Engelgau MM. Self-management education for adults with type 2 diabetes: a meta-analysis of the effect on glycemic control. Diabetes Care 2002;25:1159–1171.
- Mistry GC, Maes AL, Lasseter KC, Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension. J Clin Pharmacol 2008;48:592–598.
- Gutzwiller JP, Tschopp S, Bock A, Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J Clin Endocrinol Metab 2004;89:3055–3061.
- Hermansen K, Kipnes M, Luo E, Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 2007;9:733–745.
- Pratley RE, Kipnes MS, Fleck PR, Wilson C, Mekki Q, Alogliptin Study 007 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy. Diabetes Obes Metab 2009;11:167–176.
- Garber AJ, Foley JE, Banerji MA, Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea. Diabetes Obes Metab 2008;10:1047–1056.
- Aaboe K, Knop FK, Vilsboll T, KATP Channel closure ameliorates the impaired insulinotropic effect of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. J Clin Endocrinol Metab 2009;94:603–608.